Angiotensin-Converting Enzyme Inhibitor Associated Cough: Deceptive Information from the Physicians' Desk Reference

被引:77
作者
Bangalore, Sripal [2 ]
Kumar, Sunil
Messerli, Franz H. [1 ]
机构
[1] Columbia Univ, Coll Phys & Surg, St Lukes Roosevelt Hosp, Hypertens Program,Div Cardiol, New York, NY 10019 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
Angiotensin-converting enzyme inhibitors; Clinical trials; Cough; Incidence; Withdrawal; LEFT-VENTRICULAR DYSFUNCTION; QUALITY-OF-LIFE; MODERATE ESSENTIAL-HYPERTENSION; LOW-DOSE PERINDOPRIL/INDAPAMIDE; ACUTE MYOCARDIAL-INFARCTION; PLACEBO-CONTROLLED TRIAL; CORONARY-ARTERY-DISEASE; NORMAL BLOOD-PRESSURE; LONG-TERM EFFICACY; DOUBLE-BLIND;
D O I
10.1016/j.amjmed.2010.06.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Dry cough is a common, annoying adverse effect of all angiotensin-converting enzyme (ACE) inhibitors. The present study was designed to compare the rate of coughs reported in the literature with reported rates in the Physicians' Desk Reference (PDR)/drug label. METHODS: We searched MEDLINE/EMBASE/CENTRAL for articles published from 1990 to the present about randomized clinical trials (RCTs) of ACE inhibitors with a sample size of at least 100 patients in the ACE inhibitors arm with follow-up for at least 3 months and reporting the incidence or withdrawal rates due to cough. Baseline characteristics, cohort enrolled, metrics used to assess cough, incidence, and withdrawal rates due to cough were abstracted. RESULTS: One hundred twenty-five studies that satisfied our inclusion criteria enrolled 198,130 patients. The pooled weighted incidence of cough for enalapril was 11.48% (95% confidence interval [CI], 9.54% to 13.41%), which was ninefold greater compared to the reported rate in the PDR/drug label (1.3%). The pooled weighted withdrawal rate due to cough for enalapril was 2.57% (95% CI, 2.40-2.74), which was 31-fold greater compared to the reported rate in the PDR/drug label (0.1%). The incidence of cough has increased progressively over the last 2 decades with accumulating data, but it has been reported consistently several-fold less in the PDR compared to the RCTs. The results were similar for most other ACE inhibitors. CONCLUSION: The incidence of ACE inhibitor-associated cough and the withdrawal rate (the more objective metric) due to cough is significantly greater in the literature than reported in the PDR/drug label and is likely to be even greater in the real world when compared with the data from RCTs. There exists a gap between the data available from the literature and that which is presented to the consumers (prescribing physicians and patients). (C) 2010 Elsevier Inc. All rights reserved. circle The American Journal of Medicine (2010) 123, 1016-1030
引用
收藏
页码:1016 / 1030
页数:15
相关论文
共 138 条
[1]   ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension [J].
Amerena, J ;
Pappas, S ;
Ouellet, JP ;
Williams, L ;
O'Shaughessy, D .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2002, 30 (06) :543-552
[2]   Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial [J].
Andersen, Karl ;
Weinberger, Myron H. ;
Egan, Brent ;
Constance, Christian M. ;
Ali, Mohammed A. ;
Jine, James ;
Keefe, Deborah L. .
JOURNAL OF HYPERTENSION, 2008, 26 (03) :589-599
[3]  
[Anonymous], 1995, Hypertens Res, V18, P235
[4]   Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics [J].
Baba, S .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2001, 54 (03) :191-201
[5]   Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study [J].
Bakris, G. L. ;
Toto, R. D. ;
McCullough, P. A. ;
Rocha, R. ;
Purkayastha, D. ;
Davis, P. .
KIDNEY INTERNATIONAL, 2008, 73 (11) :1303-1309
[6]   Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial [J].
Bakris, G. L. ;
Ruilope, L. ;
Locatelli, F. ;
Ptaszynska, A. ;
Pieske, B. ;
de Champlain, J. ;
Weber, M. A. ;
Raz, I. .
KIDNEY INTERNATIONAL, 2007, 72 (07) :879-885
[7]  
BALCON R, 1992, CIRCULATION, V86, P100
[8]  
BALL SG, 1993, LANCET, V342, P821
[9]   Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril [J].
Black, HR ;
Graff, A ;
Shute, D ;
Stoltz, R ;
Ruff, D ;
Levine, J ;
Shi, Y ;
Mallows, S .
JOURNAL OF HUMAN HYPERTENSION, 1997, 11 (08) :483-489
[10]   Short- and long-term effects of early Fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: Results from the Fosinopril in Acute Myocardial Infarction Study [J].
Borghi, C ;
Marino, P ;
Zardini, P ;
Magnani, B ;
Collatina, S ;
Ambrosioni, E .
AMERICAN HEART JOURNAL, 1998, 136 (02) :213-225